D. Scott LaMontagne, PhD, MPH, FRSPH, CS, is an epidemiologist and director of HPV vaccine programs at PATH. He manages PATH's technical assistance team for national introductions of HPV vaccine in more than two dozen low- and middle-income countries. He is co-investigator for an HPV cost of delivery study in six countries, as well as technical officer for an alternative dosing schedule randomized controlled trial of a new bivalent HPV vaccine in Bangladesh and Ghana. He has authored and co-authored numerous papers on the clinical and operational aspects of HPV vaccine delivery in developing countries and is a recognized international expert in HPV vaccine delivery and evaluation in low-resource settings. Dr. LaMontagne has over 25 years of experience in infectious disease surveillance, operations and implementation research, public health program implementation, monitoring and evaluation, and project management for government and nongovernmental agencies at local, state, and national levels in developed and developing countries. He is a specialist in surveillance and epidemiology of human papillomavirus, Chlamydia trachomatis, tuberculosis, and sexually transmitted infections.